Table 1.
patient characteristics at inclusion
| All | Fibrosis F0/1 |
Fibrosis F≥2 | p | ||
|---|---|---|---|---|---|
| No NASH | NASH | ||||
| Patients (n) | 57 | 20 | 10 | 27 | - |
| Age (years) | 60 (51-66) | 55 (47-64) | 61 (52-70) | 62 (56-67) | 0.283 |
| Sex (M/F) | 34/23 | 13/7 | 6/4 | 15/12 | 0.808 |
| BMI (kg/m2) | 31 (28-34) | 30 (26-34) | 31 (28-32) | 32 (29-35) | 0.268 |
| Diabetes (no/yes)a | 30/27 | 18/2 | 5/5 | 7/20 | <0.001 |
| Elevated blood pressure (no/yes)b | 14/43 | 10/10 | 1/9 | 3/24 | 0.005 |
| Elevated triglycerides (no/yes)c | 28/29 | 15/5 | 4/6 | 9/18 | 0.015 |
| Reduced HDL-cholesterol (no/yes)d | 14/43 | 6/14 | 1/9 | 7/20 | 0.475 |
| Metabolic syndrome (no/yes) | 11/46 | 8/12 | 0/10 | 3/24 | 0.011 |
| AST (IU/l) | 40 (32-59) | 36 (30-43) | 32 (20-44) | 56 (37-71) | 0.002 |
| ALT (IU/l) | 64 (39-89) | 62 (29-83) | 44 (32-86) | 69 (55-102) | 0.129 |
| GammaGT (IU/l) | 80 (40-124) | 71 (39-127) | 53 (29-117) | 93 (60-159) | 0.238 |
| Us CRP (mg/l) | 1.8 (1.0-4.3) | 1.4 (0.6-2.5) | 2.9 (1.1-4.2) | 1.8 (1.3-5.8) | 0.115 |
Quantitative results are expressed as median with 1st and 3rd quartiles into brackets
a
Either anti-diabetic treatment or fasting glycemia ≥7.0 mmol/l
According to the International Diabetes Federation definition:
b
Antihypertensive treatment or elevated blood pressure with systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg
c
Lipid-lowering treatment or triglycerides ≥1.7 mmol/l
d
Lipid-lowering treatment or HDL-cholesterol <1.1 mmol/l in men or <1.3 mmol/l in women